Compare DFH & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFH | NUVB |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | United States |
| Employees | N/A | 291 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2020 | N/A |
| Metric | DFH | NUVB |
|---|---|---|
| Price | $13.96 | $4.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $26.00 | $11.38 |
| AVG Volume (30 Days) | 603.6K | ★ 3.1M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $4,322,848,000.00 | N/A |
| Revenue This Year | $0.81 | $205.55 |
| Revenue Next Year | $7.82 | $58.57 |
| P/E Ratio | $6.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.29 | $1.57 |
| 52 Week High | $31.10 | $9.75 |
| Indicator | DFH | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 41.06 | 57.00 |
| Support Level | $13.35 | $4.06 |
| Resistance Level | $14.75 | $5.55 |
| Average True Range (ATR) | 0.75 | 0.24 |
| MACD | 0.18 | 0.10 |
| Stochastic Oscillator | 40.51 | 97.11 |
Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.